Study: Dual-action drug is effective in obese diabetes patients

10/31/2013 | Reuters

A new dual-action molecule developed by Roche Holding appeared to show greater potency than single-hormone drugs in regulating metabolism in obese patients with type 2 diabetes, according to a study in Science Translational Medicine. The drug mimics the effects of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide and may also be administered to patients at a lower dosage, reducing the risk of side effects such as nausea and vomiting.

View Full Article in:


Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Payer Marketing
Avalere Health
Washington, DC
Chief Quality Officer
UnityPoint Clinic
Des Moines, ID
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX
The Pew Charitable Trusts
Director, Antibiotics and Innovation Project
Washington, DC
Senior Officer, Drugs and Medical Devices
The Pew Charitable Trusts
Washington, DC